Rabbit Polyclonal PKN1 Antibody

+ +

•  

   
     Anti-PKN1 Antibody (C-Term) at 1:2000 dilution + Jurkat whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 104 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized HeLa (human cervical epithelial adenocarcinoma cell line) cells labeling PKN1 with P34418 at 1/25 dilution, followed by Dylight® 488-conjugated goat anti-rabbit IgG  secondary antibody at 1/200 dilution (green). Immunofluorescence image showing cytoplasm and nucleus staining on HeLa cell line. Cytoplasmic actin is detected with Dylight® 554 Phalloidin  at 1/100 dilution (red). The nuclear counter stain is DAPI (blue).    

•  

   
     Overlay histogram showing Hela cells stained with P34418(green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P34418,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OE188374) at 1/200 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was rabbit IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     P34418 staining PKN1 in human heart tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,   paraffin-embedded sections).   Tissue was fixed with formaldehyde and blocked with 3% BSA for 0.  5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).   Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.   A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

The PKN1 (Protein Kinase N1) antibody is a crucial tool in studying the function and regulation of PKN1. a serine/threonine kinase belonging to the AGC kinase family. PKN1. also known as PRK1 or PKNα, plays diverse roles in cellular processes, including cytoskeletal reorganization, cell migration, apoptosis, and vesicle trafficking. It contains an N-terminal regulatory domain with three hydrophobic motifs and a C-terminal catalytic kinase domain. PKN1 is activated by Rho GTPases (e.g., RhoA, Rac1) through direct interaction, linking it to signaling pathways that regulate cell polarity, mechanotransduction, and stress responses. Dysregulation of PKN1 has been implicated in cancer progression, neurodegenerative diseases, and cardiovascular disorders, making it a potential therapeutic target.

PKN1 antibodies are widely used in Western blotting, immunofluorescence, immunohistochemistry, and co-immunoprecipitation to detect PKN1 expression, localization, and interaction partners. Specific monoclonal or polyclonal antibodies target distinct epitopes, enabling the study of post-translational modifications (e.g., phosphorylation) or conformational changes. Validated antibodies help elucidate PKN1's role in disease models, such as its pro-survival function in tumors or its involvement in amyloid-beta toxicity in Alzheimer’s disease. Researchers also utilize PKN1 antibodies to assess kinase activity inhibition in drug discovery. Cross-reactivity with homologous kinases (e.g., PKN2/3) requires careful antibody validation via knockout controls or siRNA knockdown to ensure specificity.